Target Product Profile
Optimal Medicine for Obesity
Spec-sheet requirements derived from disease biology, patient need, and translational evidence
Review
Version | February 2026
Sections A–D below are modality-agnostic product requirements. Section E defines combination partner requirements. Section F is strategic interpretation (what modality best meets the spec). These are explicitly separated.
| Parameter | Optimal | Min. Viable | How Measured | Rationale & Evidence | Go/No-Go Criterion |
|---|---|---|---|---|---|
| Weight Loss Magnitude | ≥15% placebo-adj at 52w, with continued loss 36→52w (slope ≥2pp) | ≥10% placebo-adj at 52w | Mean % change in BW; placebo-adjusted; ITT; 52w | T2D remission associated with ≥15% WL – 86% remission at ≥15kg in DiRECT [1]. OSA resolution: AHI reduced up to 62.8% vs placebo in SURMOUNT-OSA [3]. MASH improvement requires ≥10%. Slope criterion (“no plateau”): continued mean loss from wk 36→52 of ≥2 percentage points guards against pharmacological ceiling. SC semaglutide monotherapy ceiling: ~12.4% placebo-adj at 68w [7]. Tirzepatide (GLP-1+GIP): ~17.8% placebo-adj at 72w (treatment-regimen) [5]. Retatrutide (triple): ~24% placebo-adj at 48w, Phase 2 [6]. CT-388 (biased GLP-1/GIP): 22.5% placebo-adj at 48w (efficacy estimand) / 18.3% (treatment-regimen), no plateau [13]. Orforglipron 36mg (oral SM): 9.1% placebo-adj at 72w, treatment-regimen estimand [9]. Aleniglipron 240mg: 15.3% placebo-adj at 36w, still descending [12]. SC amycretin 60mg: 23.2% placebo-adj at 36w [14]. | <10% placebo-adj at 52w, OR plateau by 36–48w despite dose optimization → does not meet minimum bar for comorbidity resolution |
| Responder Rate | ≥70% achieving ≥10% WL; ≥40% achieving ≥15% WL at 52w | ≥50% achieving ≥10% WL | Categorical: % of ITT achieving ≥10%, ≥15%, ≥20% BW reduction; 52w | Mean WL masks 15–30% non-responders (<5% WL) in GLP-1 trials. FDA obesity guidance evaluates categorical thresholds. Health economics: higher responder rate = lower NNT = better cost-effectiveness per QALY. Tirzepatide 15mg: ~90% achieved ≥10% [5]. CT-388 24mg at 48w: 87% achieved ≥10% [13]. Orforglipron 36mg ATTAIN-1: 54.6% ≥10%, 36.0% ≥15% at 72w [9]. Aleniglipron 120mg at 36w: 70% ≥10% [12]. Oral absorption variability may structurally limit oral SM responder rates: HRS-7535 post-hoc showed WL correlated with drug exposure [15], suggesting non-responders may partly reflect under-absorption (see Assumption X5). | <50% achieving ≥10% at 52w → unfavorable NNT; expect payor step-therapy restrictions and limited formulary access |
| Durability | Weight maintained through 104w on-therapy; characterized regain trajectory off-therapy | Sustained efficacy through 72w with no tachyphylaxis signal | Mean % change BW at 104w vs nadir; on-therapy + off-therapy arms; ITT | STEP 1 extension: ~2/3 of WL regained within 1yr of semaglutide discontinuation [7]. Obesity requires indefinite treatment. 104w data also tests whether oral bioavailability remains consistent with chronic dosing (GI adaptation, receptor desensitization). No oral SM has data beyond 72 weeks. ATTAIN-MAINTAIN showed orforglipron maintained weight after switch from Wegovy (avg difference 0.9kg at 52w) [11], supporting oral SM durability but from injectable switch, not de novo. | On-therapy regain after achieving nadir (tachyphylaxis signal) → mechanism/PK reassessment. Off-therapy regain is expected but must be quantified for chronic-use labeling. |
| Body Composition | >75% of total WL from fat mass (DEXA); lean mass preservation | >65% from fat mass; no accelerated muscle wasting signal | DEXA-derived fat mass and lean mass change at 52w; fat:lean ratio of WL | GLP-1 monotherapy: ~25–40% of WL from lean mass. Lean mass loss reduces resting metabolic rate (accelerating regain), impairs function (>55y), may worsen mortality. Tirzepatide SURMOUNT-1: ~3:1 fat:lean ratio (~25% lean) [5]. No oral SM has reported DEXA data. Aleniglipron body composition study (N=71, interim): tolerability data only (0% AE disc at 2.5mg start), no DEXA-derived lean:fat ratio reported [12]. This is a critical gap – oral SM body composition outcomes are assumed identical to injectable peptides (same GLP-1R target) but unvalidated (see Assumption P4). | >40% of WL from lean mass without mitigation strategy → body composition preservation partner required (see Section E, Strategy 3) |
| Parameter | Optimal | Min. Viable | How Measured | Rationale & Evidence | Go/No-Go Criterion |
|---|---|---|---|---|---|
| Dosing Frequency | QD oral (no fasting, no water restriction) or monthly+ injectable | QD oral (any conditions) or QW injectable | Prescribed regimen; real-world persistence at 12mo | Real-world GLP-1 RA adherence: 40–70% discontinuation at 12 months across injectable formulations. QD oral without food restrictions is the convenience bar. BID oral is unacceptable – danuglipron BID contributed to >50% total discontinuation. MariTide’s ~21-day T½ enables monthly dosing, redefining the injectable bar. Gen 3c modality (VRB-101/ecnoglutide oral + T2026 enhancer) models QW oral exposures comparable to SC semaglutide 2.4mg [16] – if validated, weekly oral dosing could further redefine the convenience bar. | BID dosing or mandatory fasting window → competitive disadvantage vs. orforglipron/aleniglipron (no restrictions). Expect adherence erosion. |
| Route Flexibility | Platform with oral (PCP entry) + injectable (efficacy escalation); no cold chain | At least one oral formulation | Modality availability; prescriber adoption rates | 80%+ of obesity managed in primary care. PCPs prefer prescribing pills. Patient preference: >70% favor oral when efficacy comparable. But some patients need injectable-level efficacy beyond oral monotherapy ceiling. Ideal: oral backbone for initiation/maintenance, injectable for escalation. Roche exemplifies this: CT-388 (injectable, 22.5% PA) + CT-996 (oral SM, Phase 1) + petrelintide (amylin combo). | Injectable-only → misses PCP prescriber pool. Oral-only → may cap efficacy for treatment-resistant patients. |
| Titration to Full Dose | ≤12 weeks to maintenance dose | ≤16 weeks | Time from first dose to target maintenance dose; protocol-defined | Each titration week = subtherapeutic exposure. Most GI AEs attenuate within 4–8 weeks at a given dose. Lower starting doses improve retention – aleniglipron 2.5mg OLE start: 0% AE discontinuation vs. 10.4% mean with 5mg start [12]. Orforglipron requires ~20 weeks (1→3→6→12→24→36mg, 4-week intervals) [9]. | >20 weeks titration → delayed therapeutic benefit, patient disengagement risk. 1-week titration steps → unacceptable nausea (danuglipron precedent). |
| GI Tolerability | Nausea <30% during titration, <10% at maintenance; AE discontinuation <5% at 52w | Nausea <50% titration; AE discontinuation <12% | TEAE incidence by phase (titration vs maintenance); AE-related discontinuation at 52w; ITT | GLP-1R nausea is Cmax-dependent (area postrema activation). Flat PK (long T½ or AUC-driven biased agonism) reduces peak exposure while maintaining hypothalamic appetite suppression. CT-388 (biased agonist, injectable): 5.9% AE discontinuation [13]. Orforglipron ATTAIN-1: 5.3–10.3% AE disc across doses, nausea 28.9–33.7% [9]. Aleniglipron: 0% AE disc at 2.5mg start, 10.4% mean at 5mg start [12]. SC amycretin 60mg: 35% total dropout at 36w [14] – incretin stacking compounds GI burden substantially. | AE discontinuation >12% at 52w despite optimized titration → not viable for primary care scale. Persistent nausea (>20%) at maintenance → mechanism/PK problem, not titration problem. |
| Parameter | Optimal | Min. Viable | How Measured | Rationale & Evidence | Go/No-Go Criterion |
|---|---|---|---|---|---|
| Hepatic Safety | Zero DILI signal across full clinical database | No Hy’s Law cases; ALT in-line with GLP-1 RA class | Hy’s Law assessment; ALT/AST monitoring; DILI adjudication | In current competitive landscape with clean alternatives, DILI is the highest-consequence safety signal. Pfizer lotiglipron: terminated Phase 1 (transaminases). Pfizer danuglipron: 1 asymptomatic DILI case in ~1,400 → program terminated. Aleniglipron: no DILI, no persistent ALT across all studies [12]. Orforglipron: no hepatic signal in Phase 3 [9]. MDR-001: ALT/AST reduced vs placebo in patients with pre-existing liver impairment [15]. | Hy’s Law case attributable to drug → program stop. Reproducible ALT/AST pattern with mechanistic concern (reactive metabolite, mitochondrial toxicity) → stop. Isolated transient ALT elevation without pattern → enhanced monitoring, not automatic stop. |
| CV Safety | CV benefit (MACE reduction) for label expansion | CV neutral: no QTc prolongation, no dose-related signal | CVOT (MACE: CV death, nonfatal MI, nonfatal stroke); QTc study | Semaglutide SELECT: 20% MACE reduction (HR 0.80, CI 0.72–0.90) in 17,604 patients [4]. FDA is expected to require large CV safety/outcomes programs for chronic obesity drugs (SELECT precedent), though no formal universal requirement exists yet (see Assumption R1). No oral SM has initiated a CVOT – the single largest regulatory and commercial data gap. Oral semaglutide 25mg (Wegovy oral) is now approved and has received a CV indication (MACE reduction) based on OASIS + SELECT data (Dec 2025), giving it a labeling advantage no oral SM can match without its own CVOT. | QTc prolongation signal → requires risk-benefit reassessment. Absence of CVOT data → labeling disadvantage vs semaglutide; limits prescriber confidence and payor coverage. CV signal in Phase 3 → program-threatening. |
| Other Organ Safety | No signals above background for pancreatitis, MTC, gallbladder, retinopathy | In-line with approved GLP-1 RA class rates | Standard TEAE monitoring; adjudicated organ-specific events | Known class signals: pancreatitis (~0.1–0.3%), MTC (rodent C-cell tumors, boxed warning, no human signal), gallbladder (~1–2%, weight-loss-mediated), retinopathy (transient, T2D-specific). For novel combination mechanisms: BAT activators need thermogenesis monitoring; CB1 antagonists need neuropsych monitoring; mitochondrial uncouplers need thermal safety margin. | Any signal exceeding established class rates in Phase 3 → risk-benefit reassessment, especially for obesity indication (lower baseline organ risk than T2D). |
| Parameter | Optimal | Min. Viable | How Measured | Rationale & Evidence | Go/No-Go Criterion |
|---|---|---|---|---|---|
| Synthesis | Chemical synthesis (non-recombinant); standard SM manufacturing | Recombinant peptide with established scale-up | Manufacturing process; COGS per dose; bioreactor vs. chemical | Addressable population: >890M adults with obesity [8]. Peptide manufacturing has historically been capacity-constrained: Novo >$10B, Lilly ~$9B invested; shortages persisted 2024–2025. Chemical SM manufacturing uses standard pharma infrastructure, no bioreactors, no cold chain, with linear scalability. However, Barber et al. estimate generic peptide GLP-1s could be manufactured for under $5/month [20], narrowing the historical cost gap. The remaining synthesis advantage is infrastructure simplicity, not cost magnitude. | COGS >$200/month per patient at scale → cost advantage over generic peptides narrows; access thesis weakens. |
| Storage | Room temperature stable; standard pharmacy distribution | Refrigerated acceptable for injectables; room temp required for oral | ICH stability data; cold chain requirements | Cold chain limits LMIC distribution and increases last-mile cost. Room temperature enables: standard pharmacy shelf, mail order, distribution without refrigeration, disaster resilience. For a billion-person global disease, temperature sensitivity is a meaningful barrier (see Assumption M2 for limitations). | Room temp instability for oral formulation → specialized packaging, distribution constraints, access limitation in target geographies. |
| COGS (Manufacturing) | COGS <$50/month per patient at projected scale | COGS <$100/month | COGS per dose at projected commercial scale; manufacturing process economics | <$50/month is achievable for oral SMs based on standard chemical synthesis economics, but this is no longer a strong differentiator vs generic peptides. Barber et al. (JAMA Network Open, 2024) estimated sustainable cost-based prices for GLP-1 agonists at $0.75–$72.49/month, with injectable semaglutide at ~$0.89/month under competitive generic manufacturing [20]. Novo Nordisk’s 2025 annual report explicitly anticipates generic semaglutide competition and frames it as an access opportunity rather than a threat [21]. The COGS gap between oral SMs and generic peptides is therefore likely 2–5x (not the 10–100x vs branded peptides originally assumed). Oral SM’s remaining manufacturing advantages are non-cost: no cold chain, no bioreactors, standard pharmacy distribution, and tablet co-formulation flexibility. Specific orforglipron/aleniglipron COGS are not public (see Assumption M1). | COGS advantage alone no longer sufficient to justify oral SM thesis. Strategic differentiation must rest on convenience (no cold chain, no needles, QD tablet) and co-formulation flexibility, not cost. If generic peptide COGS reach <$5/month, oral SM cost argument is neutralised. |
| Payor Affordability (Net Price) | Net price consistent with broad formulary coverage without step-therapy or restrictive PA | Net price enabling at least Tier 2–3 formulary placement with standard PA | Net price vs payor budget-impact thresholds; formulary tier; PA/step-therapy requirements | Branded injectable GLP-1 RAs: $800–$1,300/month US list – unsustainable at population scale. IRA + reference pricing compressing margins. Broad payor coverage without restrictive PA requires net price substantially below current branded levels. The threshold is payor-specific and not publicly standardized. | Net price at or above branded injectable GLP-1 level → no access advantage despite lower COGS. Payor coverage restricted to step-therapy after injectable failure. |
| Patient Affordability (OOP) | Typical patient OOP ≤$50/month in at least one major access channel | OOP comparable to generic Tier 1–2 copay in commercial formularies | Patient copay at point of sale; availability of copay assistance / government programs | CMS BALANCE demonstration: eligible Medicare beneficiaries will pay $50/month for GLP-1 medications [19]. This establishes $50/month as a validated patient affordability benchmark for government-sponsored access. Critically, ≤$50 OOP is already being achieved for branded injectable peptides: Novo Nordisk reports that >85% of Wegovy patients pay $50 or less per prescription in the US commercial channel, through formulary negotiation, employer opt-in, and copay assistance programs [22]. This demonstrates that low patient OOP does not require oral SM COGS – it can be achieved through payor mechanics alone, even at ~$1,300 list price. With generic peptide competition approaching (Barber et al. estimate generic injectable semaglutide CBP at ~$0.89/month [20]), patient OOP for injectable GLP-1s will likely fall further. The oral SM patient affordability advantage is therefore minimal in markets with mature payor infrastructure. The remaining OOP advantage for oral SMs is in LMICs and self-pay markets where payor negotiation infrastructure is weak and cost tracks more closely to COGS. | OOP >$100/month without copay assistance → adherence erosion and access inequity. However, this threshold is already met by branded injectables in the US commercial channel. Oral SM’s OOP differentiation is limited to markets without mature payor infrastructure. |
Note: “$50/month” appears in three contexts in this TPP. (1) In the COGS row, it is a manufacturing target based on SM cost assumptions (Assumption M1; achievable but not meaningfully differentiated vs generic peptides – Barber et al. [20]). (2) In the Patient Affordability row, $50/month OOP is sourced from CMS BALANCE [19] as a government benchmark, but >85% of branded Wegovy patients already pay ≤$50 commercially [22]. (3) These are not equivalent: COGS, payor net price, and patient OOP are independent parameters that should not be conflated. Oral SM’s remaining access advantage is concentrated in LMICs, self-pay markets, and settings where payor infrastructure is weak and cost tracks closer to COGS.
These define what combination partners must deliver. The strategies are modality-agnostic; oral co-formulation feasibility is addressed in Section F.
| Strategy | Target Outcome | Mechanism | Key Evidence | Critical Unknowns |
|---|---|---|---|---|
| 1. Same-Axis Incretin Stacking | ≥20% placebo-adj WL at 52w from multi-target appetite suppression | GLP-1 backbone + GIP, amylin, or glucagon agonist. Layers additional anorexigenic signals converging on hypothalamic circuits. | SC amycretin (GLP-1+amylin): ~22–24% absolute WL at 36w [14]. SC amycretin 60mg: 23.2% placebo-adj at 36w, but 35% dropout; 20mg arm: ~23.9% PA with lower dropout, likely more commercially viable [14]. Tirzepatide (GLP-1+GIP): ~17.8% placebo-adj at 72w (treatment-regimen) [5]. Retatrutide (GLP-1+GIP+GcgR): ~24% placebo-adj at 48w [6]. | Will stacking compound GI AEs beyond tolerability? SC amycretin 60mg dropout (35%) suggests this risk is real at higher doses (see Assumption X2). No human oral SM combination data exists. PK interactions in co-formulated tablets unproven. |
| 2. Dual-Axis Independent Mechanisms | Additive WL from mechanistically non-overlapping pathways, potentially at lower GLP-1 doses (less nausea) | Appetite suppression (GLP-1, central) + energy expenditure (BAT thermogenesis, controlled uncoupling, or peripheral lipid metabolism). | EGS-2632: Phase 2, BAT growth. HU6: Phase 2, controlled uncoupling (HFpEF/MASH). CB1 pathway: monlunabant showed 7.1kg WL but was terminated due to neuropsych AEs indicating CNS penetration despite “peripheral” design. CRB-913 (Corbus): Phase 1a, tighter peripheral restriction, zero neuropsych signal, but too early for efficacy data. | Is human BAT volume sufficient for clinically meaningful thermogenesis? No human combination data. Energy expenditure approaches are earlier-stage (see Assumption X3). CB1 pathway narrowed to Corbus only after Novo exit. |
| 3. Body Composition Preservation | Shift WL composition to >80% fat mass while preserving lean mass | GLP-1 backbone + myostatin/activin inhibitor, APJR agonist, or ACVR modulator. Does not increase total WL; changes what is lost. | Bimagrumab: fat loss + lean gain, modest total WL. Lilly BELIEVE trial (bimagrumab + semaglutide/tirzepatide) underway. Trevogrumab + garetosmab (Regeneron): Phase 2 combo w/ semaglutide. SRK-439: preclinical. IBIO-600 (iBio): Phase 1 myostatin inhibitor. | Regulatory path for body composition co-primary endpoint is undefined (see Assumption R3). Without oral SM DEXA data, it is unknown whether body composition preservation is more or less critical for oral SMs vs injectables. May muscle preservation partially antagonize GLP-1-mediated WL? (see Assumption X4). |
This section is strategic interpretation, not TPP requirement. It assesses which modality is best positioned to meet the requirements defined in Sections A–D, contingent on stated assumptions.
The TPP parameters collectively favor oral small molecule GLP-1R agonist as the backbone format – but only if the combination architecture (Section E) works. The conclusion rests on two independent arguments: (1) convenience and distribution advantages (room temp, no fasting, no needles, PCP adoption, tablet co-formulation) are only met by oral SM, and (2) oral co-formulation flexibility enables single-tablet multi-target combinations that injectable peptides cannot replicate. Note: the COGS argument has weakened – Barber et al. [20] estimate generic peptide GLP-1s at <$5/month, narrowing the historical cost gap. The oral SM thesis now rests primarily on convenience and co-formulation, not manufacturing cost. Both arguments carry dependencies. The decision framework:
Oral SM becomes strategically dominant on the basis of patient experience: room temperature stability, no fasting, QD dosing, no needles, PCP-friendly prescribing, and single-tablet co-formulation flexibility. The COGS advantage over generic peptides is modest (perhaps 2–5x, not the 10–100x originally assumed vs branded peptides) and alone is insufficient to justify the modality choice. The patient OOP advantage is also limited: >85% of branded Wegovy patients already pay ≤$50/Rx in the US commercial channel [22], and generic peptides will drive OOP lower. The oral SM access advantage is therefore concentrated in (a) LMICs and self-pay markets where payor infrastructure is weak, (b) co-formulation flexibility enabling single-tablet combinations, and (c) patient/prescriber preference for pills over injections. The value proposition holds if combination tablets achieve ≥20% WL and patients/prescribers strongly prefer oral. The oral SM thesis depends on: (a) co-formulation PK feasibility, (b) combination tolerability, and (c) CVOT data eventually supporting broad labeling.
If oral SM monotherapy stays at ~9–15% WL and combination tablets fail to reach ≥20% (due to PK interactions, compounded GI AEs, or safety signals), injectable multi-agonists retain the efficacy advantage. Retatrutide (~24% placebo-adj, Phase 2), CagriSema, CT-388+petrelintide, and SC amycretin all exceed 20% as injectables. Monthly dosing (MariTide, 17.3% PA at 52w) addresses the convenience gap. With generic peptide COGS projected at <$5/month [20] and Novo explicitly positioning generic semaglutide as an access foundation [21], injectable generics could deliver high efficacy at low cost – removing the oral SM’s former pricing advantage. In this scenario, oral SM serves only as a primary care entry point for needle-averse patients, not as a definitive or cost-superior treatment.
VRB-101/ecnoglutide oral (with T2026 permeation enhancer) models weekly oral exposures comparable to SC semaglutide 2.4mg [16]. If Phase 2 validates this, weekly oral peptides could deliver injectable-level efficacy without needles or cold chain – partially undermining the oral SM daily-dosing convenience thesis while offering higher monotherapy efficacy. However, peptide manufacturing costs remain higher than chemical synthesis and oral peptides may still face absorption variability. This modality is Phase 1 and unvalidated but should be monitored as a potential disruptor (see Assumption M3).
This is a thesis, not a certainty. The modality conclusion follows from the access + combination arguments, not from monotherapy efficacy alone. Phase 3 combination data (expected 2027–2028) will resolve the key dependency.
Assumptions are ranked by impact on the TPP thesis. Confidence: HIGH = strong multi-source evidence; MOD = reasonable inference, incomplete validation; LOW = speculative or untested.
| ID | Assumption | Evidence Supporting | Confidence | If Wrong |
|---|---|---|---|---|
| X2 | GI AEs from oral same-axis incretin stacking are manageable | No clinical data for oral SM dual/triple combos. Injectable CagriSema had higher GI AEs than semaglutide alone. Retatrutide GI AEs partially mitigated by titration. SC amycretin 60mg: 35% dropout at 36w [14]; 20mg arm more tolerable. | LOW | If stacking 2–3 incretin targets produces >70% nausea / >15% discontinuation, oral combination thesis fails. SC amycretin 60mg dropout data suggests this risk is real at higher doses. Patients default to injectable multi-agonists. |
| X3 | Dual-axis combos (GLP-1 + energy expenditure) produce clinically meaningful additive WL | No human combination data. EGS-2632 and HU6 are monotherapy Phase 2. Theoretical basis sound but unvalidated. CB1 pathway narrowed to CRB-913 (Corbus) only after monlunabant termination. | LOW | If BAT/uncoupling adds <3–5% WL, the effort and safety risk are not justified. |
| X1 | Same-axis incretin stacking (GLP-1 + amylin/GIP) produces additive WL in oral co-formulation | SC amycretin ~22–24% at 36w. Amycretin validates stacking at the unimolecular level [14]. VRB-101+VRB-103 co-formulated comparable preclinical exposure. Oral SM co-formulation PK/PD unproven. | MOD (oral peptide) / LOW (oral SM) | If oral SM co-formulation creates PK interactions reducing exposure or increasing AEs, single-tablet thesis fails. |
| X5 | Oral bioavailability is consistent across patients for oral SM GLP-1 agonists | HRS-7535 post-hoc: WL correlated with drug exposure, suggesting inter-patient absorption variability [15]. No similar analysis published for orforglipron or aleniglipron. | LOW-MOD | If 15–30% of patients are under-absorbers, responder rates are structurally capped below injectable levels regardless of dose. NNT worsens. |
| C2 | “No plateau” at 36w predicts continued WL to 72+ weeks | Aleniglipron 36w: still-descending [12]. Retatrutide 48w: still-descending. CT-388 48w: still-descending [13]. Semaglutide plateaus ~60–68w. Orforglipron at 72w: 9.1% PA (treatment-regimen) [9]. Trajectory-based prediction. | MOD | Curve could flatten between 36–72w. Aleniglipron’s trajectory may plateau, yielding final efficacy closer to orforglipron (~9–11%). |
| P2 | Biased agonism (G-protein selective) improves GI tolerability | CT-388 (biased): 5.9% AE discontinuation [13]. Aleniglipron (biased): 0% at 2.5mg start [12]. Orforglipron (non-biased): 5.3–10.3% AE disc [9]. Correlation, not causation – PK differences may explain most of the difference. | MOD | If tolerability is purely PK-driven, biased agonism is pharmacologically interesting but not commercially differentiating. |
| P1 | Cmax-driven nausea is the primary GI tolerability driver | Danuglipron BID (high Cmax) → 73% nausea vs orforglipron QD (flat PK) → ~30% nausea. Consistent with area postrema pharmacology. | MOD-HIGH | If nausea is AUC-driven, flat PK offers no advantage. Dose reduction becomes the only tolerability lever. |
| R1 | FDA will expect/require CVOTs for chronic obesity drugs | SELECT precedent. FDA guidance signals. No formal universal requirement. | MOD-HIGH | If no CVOT required, the gap is less damaging competitively. But labeling without CV data still limits prescriber confidence. |
| M1 | Oral SM COGS advantage over generic peptides is commercially meaningful | Oral SM COGS <$50/month is achievable (standard SM economics). However, Barber et al. estimate generic injectable semaglutide at ~$0.89/month sustainable CBP [20]. Novo Nordisk 2025 annual report anticipates generic semaglutide and frames it as an access opportunity [21]. Real-world generic peptide COGS likely $5–15/month; oral SM COGS likely $20–50/month. Gap is 2–5x, not the 10–100x assumed vs branded peptides. | LOW (differentiation) / HIGH (<$50 achievability) | If generic peptide COGS reach <$5/month, the oral SM cost argument is neutralised. The modality thesis must then rest entirely on convenience (no cold chain, no needles, QD tablet) and co-formulation flexibility – not manufacturing economics. |
| M3 | Gen 3c oral peptides (non-SNAC enhancers) will not achieve weekly oral dosing comparable to injectable GLP-1s | VRB-101 Phase 1: modeled QW AUC at 90–120mg approaches SC semaglutide 2.4mg exposure [16]. Phase 2 efficacy data needed for validation. | LOW-MOD | If Gen 3c achieves weekly oral dosing with injectable-level efficacy, oral SM’s daily-dosing convenience advantage diminishes. Peptide manufacturing costs remain higher but no fasting or cold chain required. |
| C3 | Cross-trial efficacy comparisons are valid when adjusted for timepoint and placebo | Standard practice but confounded by population, titration, site effects. | LOW-MOD | Only head-to-head trials resolve definitively. The TPP relies heavily on cross-trial comparison. |
| P4 | Oral SM GLP-1 agonists produce the same lean:fat WL ratio as injectable peptides | No DEXA data for any oral SM. Same target (GLP-1R) assumed. Aleniglipron body composition study interim: tolerability data only, no DEXA results yet [12]. | LOW | Different body composition outcomes would change the combination strategy rationale. If oral SMs lose more lean mass, Strategy 3 becomes mandatory rather than optional. |
Share your details and feedback, and we'll send you a full copy via email.
All links verified Feb 2026. Peer-reviewed = journal publication. PR = company press release. Data type: PA = placebo-adjusted; ABS = absolute.
